Complete remission of critical neurohistiocytosis by vemurafenib

Philipp Euskirchen, MD
Julien Haroche, MD, PhD
Jean-François Emile, MD, PhD
Ralph Buchert, PhD
Staffan Vandersee, MD
Andreas Meisel, MD

Correspondence to Dr. Euskirchen: philipp.euskirchen@charite.de

ABSTRACT

Objective: To describe a patient with life-threatening brainstem neurohistiocytosis who recovered completely upon targeted treatment with the V600E mutation-specific BRAF inhibitor vemurafenib.

Methods: We report clinical, histologic, genetic, and sequential imaging findings, including fluorodeoxyglucose (FDG)-PET, over a follow-up period of 11 months.

Results: The patient presented with central hyperventilation, skeletal and perirenal Erdheim-Chester disease, and cutaneous Langerhans cell histiocytosis. A BRAF V600E hotspot mutation was detected in all afflicted tissues. Therapy with vemurafenib led to complete and stable clinical remission of CNS lesions and systemic disease that could be demonstrated by brain MRI and whole-body FDG-PET.

Conclusions: Neurologic involvement in Erdheim-Chester disease usually confers a poor prognosis. In this patient, vemurafenib was well-tolerated and highly efficacious for severe brainstem involvement in Erdheim-Chester disease with overlapping Langerhans cell histiocytosis. This case illustrates the heterogeneous phenotypic spectrum of neurohistiocytosis and underscores the importance of genetic testing.

Classification of evidence: This article provides Class IV evidence. This is a single observational study without controls. Neurology Neuroimmunol Neuroinflamm 2015;2:e78; doi: 10.1212/NXI.0000000000000078

GLOSSARY

CIP = critical illness polyneuropathy; ECD = Erdheim-Chester disease; FDG = fluorodeoxyglucose; LCH = Langerhans cell histiocytosis.

Histiocytosis encompasses a group of rare systemic disorders of largely unknown origin, although some forms are likely to arise from neoplastic transformation leading to proliferation of histiocytes in affected tissues. Among them, Erdheim-Chester disease (ECD), which predominantly affects adult patients, is characterized by typical symmetric infiltration of long bones as well as aortal and perirenal involvement. Here we report a case of ECD and cutaneous Langerhans cell histiocytosis (LCH) overlap syndrome with life-threatening CNS involvement due to neurogenic hyperventilation responding dramatically to targeted therapy.

CASE REPORT A 59-year-old Caucasian woman was admitted to our neurointensive care unit with altered level of consciousness after a suspected syncope. Her medical history included submammary cutaneous lesions, which were diagnosed as LCH 15 months before and treated successfully with thalidomide. In addition, after seeking medical advice for knee pain, a nontraumatic tibial fracture was diagnosed. A bone biopsy was performed and did not demonstrate a malignancy but at the time was considered otherwise nondiagnostic.

At presentation, the patient was somnolent with intact motor function and sensation. She was hyperventilating with pronounced hypocapnia (PCO₂ 12 mm Hg) and respiratory alkalosis (pH 7.6). Retrospectively, fast
breathing had been observed for weeks, as well as dysphagia, fatigue, and lethargy. MRI scans showed T2 hyperintense and partly contrast-enhancing pontine, cerebellar, cerebellar peduncle, and occipital lesions (figure 1, A and C). A chest and abdominal CT showed perirenal and periaortal fibrosis with “hairy kidney” and “coated aorta” appearance, which raised the differential diagnosis of ECD. Supporting evidence was provided by Tc99 scintigraphy, which had been performed 2 years earlier because of the abovementioned nontraumatic tibia fracture and showed symmetric bilateral Tc99 uptake in the long bones of the lower extremities (figure 2A). CSF analysis at the current presentation showed elevated lactate and protein levels but normal cell counts and glucose. The diagnosis of ECD was finally proven by a perirenal biopsy revealing diffuse infiltration of CD1a-negative histiocytes. Reevaluation of skin biopsies, however, confirmed the presence of CD1a-positive histiocytes, whereas the tibia samples showed a histiocytic infiltrate with both CD1a-negative and CD1a-positive phenotypes. Due to recent reports of frequent mutations in the B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene in both Langerhans cell and Erdheim-Chester histiocytosis,1–3 sequencing of BRAF exon 15 was performed. A heterozygous V600E point mutation was found in all lesions (perirenal, bone, and skin).

Due to respiratory failure from hyperventilation and pneumonia with subsequent sepsis, mechanical ventilation was needed. Neurogenic hyperventilation was treated by morphine application. After a course of 5 × 1 g IV methylprednisolone without clinical benefit, targeted therapy with the oral V600E mutation-specific BRAF inhibitor vemurafenib was started (960 mg twice daily). Rapid improvement in consciousness and hyperventilation was observed within weeks of treatment. Recovery was delayed due to a flaccid tetraparesis caused by critical illness polyneuropathy (CIP).

After 6 months of vemurafenib treatment, the patient had recovered completely from hyperventilation and dysphagia, mental status was normal, and CIP-related motor symptoms had resolved. Brain MRI showed remission of both T2 hyperintensities and contrast enhancement in all infratentorial lesions (figure 1, B and D). Whole-body fluorodeoxyglucose (FDG)-PET (figure 2, B and C) also showed regression of glucose uptake in bone manifestations (maximum standardized uptake values in left humerus lesions at the beginning and after 6 months of treatment: 4.0 vs 1.5). Unfortunately, lower extremities were not imaged in the baseline FDG-PET scan. Cutaneous lesions had regressed under BRAF therapy with residual erythema. C-reactive protein levels stably returned to nearly normal levels (figure 2D). To evaluate whether continuous treatment of stable disease is necessary, vemurafenib has been tapered to a maintenance dosage of 480 mg/day under careful clinical monitoring. No relapse has been observed over the clinical follow-up period of 11 months.

DISCUSSION ECD is a non-LCH with variable clinical presentation that affects multiple organs. Skeletal involvement with bilateral symmetric histiocytic infiltration of long bones, especially tibiae, as well as perirenal and periaortic infiltrations are most characteristic for the disease. Regarding CNS manifestation, which is a negative prognostic factor,4 hypophysitis, brainstem and cerebellar lesions, and, less commonly, supratentorial lesions have been described.5–7 Thus, presentation with diabetes insipidus and ataxia is common.8–10 In our case, typical infratentorial lesions were seen, even though presentation with central hyperventilation has not been described before to our knowledge. Neurogenic hyperventilation itself is a rare condition and is usually found in diffuse lesions of the pons and medulla oblongata, although association with cerebellar peduncle lesions has been described.11,12

ECD is differentiated from other forms of histiocytosis by the immunohistochemical phenotype of histiocytic lesions. Typically, lipid-laden CD68+ CD1a+ histiocytes surrounded by fibrosis are seen.13

Figure 1 MRI of brainstem manifestation

MRIs at presentation (A, C) and at 6-month follow-up (B, D) show regression of T2 hyperintensities (A, C) and contrast enhancement (B, D) under vemurafenib treatment.
BRAF mutations have recently been described in both LCH and ECD. Here we describe an overlap of both diseases and could verify the key mutation in 3 afflicted organs. Since a brain biopsy was not performed due to the delicate localization of the lesions, it remains unclear whether the CNS infiltration would show CD1a-negative or -positive histiocytes and allow a classification of either ECD or LCH. However, the occasional finding of BRAF mutations in ECD and LCH lesions within the same patient lends further support to the hypothesis that both diseases are of common origin.

For treatment of ECD, use of interferon α, imatinib, cladribine, and recombinant interleukin-1 receptor have been reported, while earlier treatment regimens included steroids and cytotoxic agents. Targeted therapy with vemurafenib has initially been reported in 3 cases, and CNS efficacy was recently demonstrated in a patient with suprasellar ECD and a case of temporal histiocytic sarcoma. Despite severe brainstem involvement, our patient recovered completely upon continuing treatment with vemurafenib. Targeted treatment thus provides an option even when the parenchymal CNS is affected and underscores the importance of BRAF mutation screening in histiocytosis. We continued vemurafenib administration to achieve permanent remission, but prospective studies are needed to investigate maintenance treatment regimens and tolerance.

**AUTHOR CONTRIBUTIONS**

Dr. Euskirchen: study concept and design, drafting and revising the manuscript. Dr. Haroche: analysis and interpretation of clinical and imaging data. Dr. Emile: acquisition, analysis, and interpretation of histologic data. Dr. Buchert: acquisition, analysis, and interpretation of PET imaging data. Dr. Vandersee: analysis and interpretation of clinical data. Dr. Meisel: study supervision, interpretation of clinical data, drafting and revising the manuscript. All authors approved submission of the manuscript.

**ACKNOWLEDGMENT**

The authors acknowledge Joachim Röwert-Huber, Korinna Jöhrens, and Ioannis Anagnostopoulos for performing histologic analysis and genotyping.

**STUDY FUNDING**

This study was supported by the German Research Foundation (Exc 257, SFB TRR43, to Andreas Meisel).

**DISCLOSURE**

P. Euskirchen has received research support from Berliner Krebsgesellschaft and Einstein Foundation Berlin. J. Haroche has received honoraria from GlaxoSmithKline. J.-F. Emile has received honoraria from Roche and GlaxoSmithKline and has received research support from Roche. R. Buchert and S. Vandersee report no disclosures. A. Meisel is on the editorial board for PLOS ONE and the Journal of Cerebral Blood Flow & Metabolism; has a patent application for the anti-infective and immunomodulatory agents used for preventive antibacterial therapy after stroke; has consulted for Biomarin, Atheneum Partners GmbH, Sanofi Aventis, and Grifols; has received research support from BRAHMS Thermofischer Scientific, SIEMENS HealthCare Diagnostics GmbH, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, and European Union’s Seventh Framework Programme. Go to Neurology.org for full disclosures.

Received November 18, 2014. Accepted in final form January 7, 2015.

**REFERENCES**

1. Badalian-Very G, Vergilio JA, Degan BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919–1923.
2. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:2700–2703.

3. Cangi MG, Biavasco R, Cavalli G, et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis Epub 2014 March 26. doi: 10.1136/annrheumdis-2013-204924.

4. Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:2778–2782.

5. Van der Knaap MS, Arts WF, Garbern JY, et al. Cerebellar leukoencephalopathy: most likely histiocytosis-related. Neurology 2008;71:1361–1367.

6. Bianco F, Iacovelli E, Tinelli E, Locuratolo N, Pauri F, Fattapposta F. Characteristic brain MRI appearance of Erdheim-Chester disease. Neurology 2009;73:2120–2122.

7. Sedrak P, Ketonen L, Hou P, et al. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol 2011;32:2126–2131.

8. Lefaucheur R, Maltête D, Haroche J, Borden A, Wallon D, Bourre B. Teaching neuroimages: ataxia and diabetes insipidus. Neurology 2013;81:e19.

9. Liotta EM, Jhaveri MD, Fox JC, Parameswaran V, Lewis SL. Erdheim-Chester disease. Arch Neurol 2012;69:1514–1515.

10. Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013;72:1691–1695.

11. Ledet D, Delos Santos NM, Khan R, Gajjar A, Broniscer A. Central neurogenic hyperventilation and renal tubular acidosis in children with pontine gliomas. Neurology 2014;82:1099–1100.

12. Tarulli AW, Lim C, Bui JD, Saper CB, Alexander MP. Central neurogenic hyperventilation: a case report and discussion of pathophysiology. Arch Neurol 2005;62:1632–1634.

13. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012;24:53–59.

14. Caoduro C, Ungureanu CM, Rudenko B, et al. 18F-fluoride PET/CT aspect of an unusual case of Erdheim-Chester disease with histologic features of Langerhans cell histiocytosis. Clin Nucl Med 2013;38:541–542.

15. Pineses SL, Liu GT, Azabes X, et al. Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J Neuroophthalmol 2011;31:217–223.

16. Hervier B, Haroche J, Arnaud L, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 2014;124:1119–1126.

17. Haroche J, Cohen-Aubart F, Emile J-F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013;121:1495–1500.

18. Cohen-Aubart F, Emile JF, Maksud P, et al. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology 2014;83:1294–1296.

19. Idbaih A, Mokhtari K, Emile JF, et al. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 2014;83:1478–1480.
Complete remission of critical neurohistiocytosis by vemurafenib
Philipp Euskirchen, Julien Haroche, Jean-François Emile, et al.
*Neurol Neuroimmunol Neuroinflamm* 2015;2;
DOI 10.1212/NXI.0000000000000078

This information is current as of February 26, 2015
